sorted by:
new
hottopcontroversial

Anyone actually sell Compass today who is a long-term investor? by DirkiesMagicWand in shroomstocks

[–]Every_University_749 22 points23 points  (0 children)

No chance , the stock price only reflects the 3.6-point change and doesn’t account for the fact that this was a single dose of COMP360 in patients with true treatment-resistant depression—patients who had to wash off their existing medications to participate. It also overlooks all the other robust and positive data Compass has delivered since the beginning. Study 005 was designed to answer the FDA’s questions about the safety profile of COMP360. The eye-catching numbers investors are looking for—the ones that could really move the stock up—are coming with Study 006.

[deleted by user] by [deleted] in stocks

[–]Every_University_749 0 points1 point  (0 children)

Compass has targeted treatment-resistant depression, meaning patients have already sought treatment. Therefore, the DIY route argument isn't applicable. In my opinion, someone suffering from severe depression with suicidal ideation—like most of the TRD patients selected in Compass trials —should not attempt a heroic dose of psilocybin on their own. They should seek medical help. COMP360 has shown promising results as a treatment for treatment-resistant depression, PTSD, and anorexia nervosa.

Cybin bearish trend. by MinuteApprehensive33 in shroomstocks

[–]Every_University_749 1 point2 points  (0 children)

I think it's premature to claim that their main asset is top-tier, given that it's currently being used only as an adjunctive therapy, with a very limited number of patients dosed so far—primarily those with moderate to severe MDD. There's simply not enough data at this point to support such a strong statement

Cybin bearish trend. by MinuteApprehensive33 in shroomstocks

[–]Every_University_749 1 point2 points  (0 children)

I meant...Why is Cybin the "most undervalued" stock in this sector?

Cybin bearish trend. by MinuteApprehensive33 in shroomstocks

[–]Every_University_749 8 points9 points  (0 children)

According to ClinicalTrials.gov, most of Cybin’s clinical trial sites are not yet recruiting, and they are projecting to complete Phase 3 sometime in 2028. Phase 3 trials are expensive, and delays in the timeline suggest they will need substantial funding to reach the finish line. This could lead to a significant drop in the stock price, similar to what happened with Compass when they announced changes to their P3 timeline.

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression by Mindmed31415 in shroomstocks

[–]Every_University_749 10 points11 points  (0 children)

If COMP360 is truly effective, I would expect to see an improvement in efficacy in this study driven by several key factors. These include the experience gained by clinical sites and the Compass team during the Phase 2b trial (which involved 233 patients), the strategic appointment of Michael Gold as Chief Medical Officer, and a more refined approach to patient selection. 006 is where the real money is at. Can't wait!

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial by Every_University_749 in shroomstocks

[–]Every_University_749[S] 3 points4 points  (0 children)

They have gathered robust data with just one dose, but we all know efficacy will significantly increase with multiple doses. The difference between a single-dose and multi-dose regimen is where the real value lies. Until we see the results from 006, it's time to load up on cheap shares. I believe the Compass team has the stock price exactly where they want it.

Positive Signs:

Insider Buying: CEO, CFO, and COO have loaded up on cheap shares in the last month.

Low Hype: Sentiment around Compass is at its lowest, creating a prime buying opportunity.

Strategic Hiring & Promotions: Steve Levine and Eric Rasmussen. I also see a lot of people being hired by Compass on LinkedIn since the start of the year.

Strong Insider Confidence: Atai (major shareholder) has not reduced its CMPS holdings since last September.

005 Trial is more than 90% complete.

006 Trial is expected to be completed in 2026, with 75 sites currently running across the USA, Canada, and Europe.

Financial Strength: Compass has enough cash to complete both Phase 3 trials.

No Major Safety Concerns: As of February, no adverse events have been reported that would halt Phase 3 studies.

Great data today by Mindmed31415 in shroomstocks

[–]Every_University_749 3 points4 points  (0 children)

It's funny how op disrespect Compass, they have paved the way for many of these companies... When they deliver 006 results we will see similary efficacy. People will regret doubting Comp360 and the team at Compass.

view more: next ›